新闻稿Aug 29. 2019 13:52 GMT

全球领先的生物科技公司科汉森控股公司 (Chr. Hansen Holding A/S) 与领先的制药公司龙沙集团 (Lonza AG) 今日宣布,他们已经获得反垄断监管机构的相关审查批准文件,经同意可在新兴市场成立各占 50% 股份的合资公司以生产活性生物治疗产品,该消息最初已于2019 年 4 月 2 日在第 04 号公司公告中发布。

今后,该合资公司将以 BacThera 的名义运营,总部设在瑞士巴塞尔。BacThera 是 bacteriology(细菌)、therapeutic(治疗)和 era(纪元)三个单词的组合简写,它清楚地反映了公司的目标,即让客户能够为患者带来改变生活的治疗方法,并引领活性生物治疗行业的发展。现在获批运营后,BacThera 将开始为第一批客户提供服务。

在接下来的几个月中,BacThera 将升级位于丹麦赫斯霍尔姆的现有工厂,并在瑞士巴塞尔装备新厂,为二期项目提供临床前服务。随着渠道的成熟,将为三期和商业生产进一步投入设施。三年时间将总共投入 9,000 万欧元,由科汉森和龙沙平均分摊,此后,预计 BacThera 基本能实现自给自足。


Chr. Hansen is a leading, global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. We develop and produce cultures, enzymes, probiotics and natural colors for a rich variety of foods, confectionery, beverages, dietary supplements and even animal feed and plant protection. Our product innovation is based on more than 30,000 microbial strains – we like to refer to them as ‘good bacteria’. Our solutions enable food manufacturers to produce more with less – while also reducing the use of chemicals and other synthetic additives – which make our products highly relevant in today’s world. Sustainability is an integral part of Chr. Hansen’s vision to improve food and health. In 2019 Chr. Hansen was ranked as the world’s most sustainable company by Corporate Knights thanks to our strong sustainability efforts and our many collaborative partnerships with our customers. We have been delivering value to our partners – and, ultimately, end consumers worldwide – for over 140 years. We are proud that more than one billion people consume products containing our natural ingredients every day. Revenue in the 2017/18 financial year was EUR 1,097 million. Chr. Hansen was founded in 1874 and is listed on Nasdaq Copenhagen.